Despite the opportunities afforded by these multiple approaches, the development of IDO-1 inhibitors for the treatment of neurological disorders such as depression or dementia must confront a myriad of efficacy and ADMET (absorption, distribution, metabolism, excretion and toxicity) design challenges. This evidence concerns the gene IDO1 and major depressive disorder.